The Queen’s University of Belfast Confidence in Concept programme 2016
Lead Research Organisation:
Queen's University Belfast
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
Publications
Vilà-González M
(2019)
Enhanced Function of Induced Pluripotent Stem Cell-Derived Endothelial Cells Through ESM1 Signaling.
in Stem cells (Dayton, Ohio)
| Description | "The role of extracellular vesicle miRNAs in Mesenchymal Stem Cells' effects on macrophage modulation in ARDS" |
| Amount | £566,892 (GBP) |
| Funding ID | MR/S009426/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 04/2022 |
| Description | A conserved protein O-glycosylation pathway in the Burkholderia genus essential for bacterial fitness and antigenicity in humans |
| Amount | £455,987 (GBP) |
| Funding ID | BB/T005807/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2020 |
| End | 10/2023 |
| Description | Cell therapy for chronic non-healing wounds |
| Amount | £207,476 (GBP) |
| Funding ID | MR/S036695/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 02/2022 |
| Description | Development of a novel tumour immunotherapy neoantigen vaccine |
| Amount | £148,684 (GBP) |
| Funding ID | INI PoC 703 |
| Organisation | Invest Northern Ireland |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 10/2019 |
| Description | Development of intracellular VNARs as novel tools to dissect intracellular biological processes |
| Amount | £346,537 (GBP) |
| Funding ID | BB/R009112/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2021 |
| Description | Induced Pluripotent Stem Cell technology for Drug Discovery and Personalized Medicine |
| Amount | £206,360 (GBP) |
| Funding ID | 45418 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 11/2022 |
| Description | Mesenchymal stem cell-derived extracellular vesicles as a cell-free therapy for ARDS. |
| Amount | £251,900 (GBP) |
| Funding ID | MR/R025096/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2020 |
| Description | New insights into the molecular mechanisms of Grem1-mediated diabetic kidney disease |
| Amount | £112,467 (GBP) |
| Funding ID | INI PoC 905 |
| Organisation | Invest Northern Ireland |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 04/2022 |
| Description | investigation of Aberrant QKI splicing |
| Amount | £264,386 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 02/2022 |
| Title | A NEW BIOMARKER FOR PREECLAMPSIA |
| Description | This invention relates to the use of biomarker LRG1 as a biomarker for preeclampsia for use from the first trimester. Elevated levels of leucine-rich alpha 2 glycoprotein 1 (LRG1) can predict risk for the future development of preeclampsia or other hypertensive disorders of pregnancy. The predictive test will comprise the measurement of LRG1 protein, peptide fragment, DNA or RNA, from either blood, plasma, serum, urine, saliva or amniotic fluid. The invention provides a method and a test kit to assess the risk of pre-eclampsia in pregnant woman. The method or test can utilise antibodies to measure levels of LGR1 in a sample. |
| IP Reference | US2019383822 |
| Protection | Patent granted |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | N/A |
| Company Name | MICARE TECHNOLOGIES LTD |
| Description | miCARE Technologies is a real-time, integrated, home monitoring system to support healthcare in diabetes and reduce cost and stress of hospital visits. It's goal is to improve the management and outcomes of high-risk patients through risk-stratification and prediction algorithms for early detection of complications, which can be incorporated into our home monitoring system. Current application focus is on monitoring diabetes in pregnancy, but can be modified and scaled to other indications. |
| Year Established | 2018 |
| Impact | N/A |